DBV Technologies (DBVT) Liabilities and Shareholders Equity (2014 - 2026)
DBV Technologies (DBVT) reported Liabilities and Shareholders Equity of $266.4 million for Q1 2026, up 426.88% year-over-year from $50.6 million in Q1 2025, and up 13.99% on a QoQ basis from $233.7 million in Q4 2025.
DBV Technologies (DBVT) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $266.4 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 426.88% year-over-year to $266.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $754.0 million (up 133.11% YoY) and the FY2025 annual result came in at $233.7 million, up 255.94% from the prior year.
- Liabilities and Shareholders Equity climbed to $266.4 million in Q1 2026 per DBVT's latest filing, from $233.7 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $285.0 million in Q2 2022 and bottomed at $50.6 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $183.0 million (2023), against an average of $173.2 million.
- The widest annual swing landed in 2025, when Liabilities and Shareholders Equity sank 65.34%; it then surged 426.88% in 2026.
- Tracing DBVT's Liabilities and Shareholders Equity over 5 years: stood at $246.5 million in 2022, then declined by 25.77% to $183.0 million in 2023, then plunged by 64.12% to $65.7 million in 2024, then soared by 255.94% to $233.7 million in 2025, then rose by 13.99% to $266.4 million in 2026.
- Per Business Quant, the three latest DBVT Liabilities and Shareholders Equity figures stand at $266.4 million (Q1 2026), $233.7 million (Q4 2025), and $110.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 14.93 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.37 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.73 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 78.88 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 33.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.48 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 23.64 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.87 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.13 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 266.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 266.40 Mn |
| Dec 31, 2025 | 233.70 Mn |
| Sep 30, 2025 | 110.50 Mn |
| Jun 30, 2025 | 143.43 Mn |
| Mar 31, 2025 | 50.56 Mn |
| Dec 31, 2024 | 65.66 Mn |
| Sep 30, 2024 | 93.06 Mn |
| Jun 30, 2024 | 114.19 Mn |
| Mar 31, 2024 | 145.90 Mn |
| Dec 31, 2023 | 182.99 Mn |
| Sep 30, 2023 | 189.78 Mn |
| Jun 30, 2023 | 217.52 Mn |
| Mar 31, 2023 | 232.93 Mn |
| Dec 31, 2022 | 246.52 Mn |
| Sep 30, 2022 | 248.12 Mn |
| Jun 30, 2022 | 284.98 Mn |
| Mar 31, 2022 | 117.58 Mn |
| Dec 31, 2021 | 146.72 Mn |
| Sep 30, 2021 | 170.92 Mn |
| Jun 30, 2021 | 200.58 Mn |
| Mar 31, 2021 | 221.41 Mn |
| Dec 31, 2020 | 272.25 Mn |
| Jun 30, 2020 | 330.06 Mn |
| Dec 31, 2019 | 267.29 Mn |
| Sep 30, 2019 | 171.68 Mn |
| Jun 30, 2019 | 209.74 Mn |
| Dec 31, 2018 | 196.03 Mn |
| Jun 30, 2018 | 298.68 Mn |
| Dec 31, 2017 | 209.36 Mn |
| Jun 30, 2017 | 261.59 Mn |
| Dec 31, 2016 | 310.42 Mn |
| Jun 30, 2016 | 370.67 Mn |
| Dec 31, 2015 | 376.28 Mn |
| Jun 30, 2015 | 131.52 Mn |
| Dec 31, 2014 | 156.75 Mn |